Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study

Main Article Content

Kristian Reich
Mark Goodfield
Lawrence Green
Kristine Nograles
Eugenia Levi
Richard GB Langley

Keywords

safety, efficacy, apremilast, psoriasis

Abstract

Abstract Not Available

 

Disclosure: Study supported by Celgene.